Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azeliragon in MGMT Unmethylated Glioblastoma
NCT05986851Phase 2Active, not recruiting
- Sponsor
- Cantex Pharmaceuticals, Inc.
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azeliragon in glioblastoma (GBM), sponsored by Cantex Pharmaceuticals, Inc. Primary endpoint: Progression-free survival at 2 years. Started Sep 2023; status: active, not recruiting.
02
Drugs
azeliragon
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05986851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05986851.